Project Description

Hepatitis C virus (HCV) is the causal agent of hepatitis C. HCV infects over 170 million people worldwide and chronic infection can lead to cirrhosis, liver failure, and liver cancer. The standard therapy is a combination of peginterferon and ribavirin, with either boceprevir or telaprevir added in some cases. Currently no vaccine against hepatitis C is available.

Reference:

1. Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS pathogens 8, e1002832, doi:10.1371/journal.ppat.1002832 (2012).